Get the Stockscreener App
13.00
2.93%
0.37
Adaptive Biotechnologies Corp stock is traded at $13.00, with a volume of 1.95M.
It is up +2.93% in the last 24 hours and up +23.46% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$12.63
Open:
$12.68
24h Volume:
1.95M
Relative Volume:
1.02
Market Cap:
$1.98B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-9.7015
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-0.31%
1M Performance:
+23.46%
6M Performance:
+57.19%
1Y Performance:
+195.45%
1-Day Range:
$12.57
$13.39
1-Week Range:
$11.92
$13.39
52-Week Range:
$3.981
$13.39
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
13.00 | 1.89B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
How a Genentech cancer-fighting collaboration once valued at $2 billion ended with only $310 million paid out - The Business Journals
Adaptive Biotechnologies to end Genentech collaboration agreement in February 2026 - Investing.com
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Adaptive Biotechnologies Outpaces Medical Sector with 109.2% Year-to-Date Gain - AInvest
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Adaptive Biotechnologies Reaches Analyst Target Price - Nasdaq
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Just Reported And Analysts Have Been Lifting Their Price Targets - ca.finance.yahoo.com
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences - 富途牛牛
Adaptive Biotechnologies’ Earnings Call Highlights Growth - The Globe and Mail
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2025 Earnings Call Transcript - Insider Monkey
A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $14 to $15 - 富途牛牛
Adaptive Biotechnologies Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JP Morgan Boosts Price Target for ADPT to $14.00, Maintains Over - GuruFocus
JP Morgan Boosts Price Target for ADPT to $14.00, Maintains Overweight Rating | ADPT Stock News - GuruFocus
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday - Yahoo Finance
JP Morgan Maintains Overweight on Adaptive, Raises PT to $14 from $10 - AInvest
Adaptive Biotechnologies (ADPT) Rating Update: TD Cowen Raises Price Target | ADPT Stock News - GuruFocus
TD Cowen Keeps Buy Rating, Raises PT to $15 on Adaptive Biotechnologies - AInvest
Piper Sandler Raises Price Target for ADPT to $15.00 | ADPT Stock News - GuruFocus
A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $11 to $15 - 富途牛牛
Adaptive Biotechnologies stock hits 52-week high at $12.50 - Investing.com India
Adaptive Biotechnologies stock hits 52-week high at $12.50 By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (ADPT) Price Target Increased by JPMorg - GuruFocus
Adaptive Biotechnologies Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Adaptive Biotechnologies: Q2 Earnings Snapshot - New Haven Register
Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... - Yahoo Finance
Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highl - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... By GuruFocus - Investing.com Canada
Advanced analytics toolkit walkthrough for Adaptive Biotechnologies CorporationFree Swing Trading Entry Point Signals - Newser
Adaptive Biotechnologies Q2 2025 slides: MRD business achieves profitability milestone - Investing.com Nigeria
Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings - Yahoo Finance
Adaptive Biotechnologies’ MRD Business Powers Past Expectations - Finimize
Adaptive Biotechnologies (ADPT) Surpasses Revenue Expectations i - GuruFocus
Earnings call transcript: Adaptive Biotechnologies beats Q2 2025 forecasts By Investing.com - Investing.com Australia
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Adaptive Biotechnologies beats Q2 2025 forecasts - Investing.com
Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability - Investing.com
Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability By Investing.com - Investing.com UK
Adaptive Biotechnologies earnings beat by $0.07, revenue topped estimates - Investing.com South Africa
Adaptive Biotechnologies Corp SEC 10-Q Report - TradingView
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results - TradingView
How Adaptive Biotechnologies Corporation stock reacts to Fed policy changesFree Consistent Gain Investment Strategies - Newser
Top chart patterns to watch in Adaptive Biotechnologies CorporationFundamental Analysis for Value Stock Selection - Newser
Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Nee - GuruFocus
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptive Biotechnologies Corp Stock (ADPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Option Exercise |
6.32 |
68,412 |
432,364 |
1,347,936 |
| ROBINS HARLAN S | Chief Scientific Officer |
May 01 '25 |
Sale |
7.35 |
68,412 |
502,828 |
1,279,524 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):